Marketing authorisations which are recommended for suspension and marketing authorisation applications which do not satisfy the criteria for authorisation as adopted by the CHMP on 21 July 2016

First Page		Document Content
Date: 2016-07-22 09:17:34 Chemistry Business Organic chemistry Combination drugs Ethers Amines Erlotinib Pfizer Quinazolines Teva Pharmaceutical Industries Atovaquone/proguanil Novartis		Marketing authorisations which are recommended for suspension and marketing authorisation applications which do not satisfy the criteria for authorisation as adopted by the CHMP on 21 July 2016 Add to Reading List Source URL: www.ema.europa.eu Download Document from Source Website File Size: 281,50 KB Share Document on Facebook

	EZ-SCREEN® CUP Package Insert-II The EZ-SCREEN® Cup products are rapid qualitative screening assays for the detection of any combination of the following drugs or their metabolites in human urine: Amphetamine, Barbitu DocID: 1vnGd - View Document
	SCUDEM 2017 Problem B - Drug Interactions Patients undergoing medical treatment may be given a combination of drug therapies, and the information about the interaction between drugs can be limited[1]. One commonly prescr DocID: 1uSqq - View Document
	Case 3:16-cvDocument 1 FiledPage 1 ofDorian S. Berger, CA State Bar NoDaniel P. Hipskind, CA State Bar No DocID: 1rqYi - View Document
	As at AugustAstraZeneca’s Environmental Risk Summaries As part of AstraZeneca’s ongoing commitment to environmental data transparency, this website provides environmental risk summaries for the Active Pharmace DocID: 1rlq4 - View Document
	EISAI AND PIQUR SIGN LANDMARK COLLABORATION AGREEMENT TO INVESTIGATE HALAVEN® (ERIBULIN) AND PQR309 IN HARD TO TREAT FORM OF BREAST CANCER Agreement will see eribulin used in combination with novel PI3K/mTOR inhibitor i DocID: 1rhhk - View Document